Last reviewed · How we verify
Vasoactive drug therapies — Competitive Intelligence Brief
phase 3
Vasoactive agent / Sympathomimetic
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Vasoactive drug therapies (Vasoactive drug therapies) — Gruppo Italiano Multidisciplinare per lo Studio della Sincope. Vasoactive drug therapies work by modulating vascular tone and blood pressure through sympathomimetic or vasodilatory mechanisms to prevent syncope and improve cardiovascular stability.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vasoactive drug therapies TARGET | Vasoactive drug therapies | Gruppo Italiano Multidisciplinare per lo Studio della Sincope | phase 3 | Vasoactive agent / Sympathomimetic |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Vasoactive agent / Sympathomimetic class)
- Gruppo Italiano Multidisciplinare per lo Studio della Sincope · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vasoactive drug therapies CI watch — RSS
- Vasoactive drug therapies CI watch — Atom
- Vasoactive drug therapies CI watch — JSON
- Vasoactive drug therapies alone — RSS
- Whole Vasoactive agent / Sympathomimetic class — RSS
Cite this brief
Drug Landscape (2026). Vasoactive drug therapies — Competitive Intelligence Brief. https://druglandscape.com/ci/vasoactive-drug-therapies. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab